MarketInOut Stock Screener Log In | Sign Up

Century Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Century Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization271.61 mln
Float123 mln
Earnings Date11/05/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

88 / 100
Strongly outperforming

Debt / Equity

0.17
Very low leverage

ROE

-52.67
Deeply negative

ROA

-40.17
Deeply negative

Business Description

Century Therapeutics is a Philadelphia-based biotechnology company founded in 2018 that develops off-the-shelf cell therapies to treat blood cancers, solid tumors, and autoimmune diseases. Its pipeline includes several advanced cell therapy candidates, most notably a beta cell replacement therapy for type 1 diabetes and two engineered immune cell therapies targeting B-cell-driven autoimmune conditions. All of its programs are built on a shared technology platform designed to help transplanted cells avoid rejection by the patient's immune system.

Key Fundamentals

EPS-0.93
ROE-52.67
ROIC-73.02
ROA-40.17
EBITDA, mln-97.56
EV / EBITDA-2.49
EV / EBIT-2.22
Revenue, mln109
EV / Revenue2.23

Quote Details

Last 1.47
Change 0.01 (0.68%)
Open 1.46
Volume 951,059
Turnover 1,398,057
Average Volume 1,045,106

Financial Ratios

Leverage Ratio1.24
Current Ratio8.28
Price / Book1.13
Price / Tangible Book1.32
Debt / Equity0.17
Price / Sales1.15

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio37.58
Short % of Float16.21

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.68% 69 / 100   
1 Month -8.7% 31 / 100   
2 Months -29.67% 17 / 100   
6 Months -36.36% 18 / 100   
1 Year 155% 99 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog